A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer

Year : 2025 | Volume : 15 | Issue : 01 | Page : 30 40
    By

    Neha D. Patil,

  • Divakar R. Patil,

  • Akash S. Jain,

  • Azam Z. Shaikh,

  1. B. Pharm. Student, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  2. Assistant Professor, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  3. Assistant Professor, Department of Quality Assurance, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  4. Principal, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India

Abstract

Among cervical tumor-related deaths worldwide, cervical cancer is a major cause. The limitations of traditional methods, such as chemotherapy and radiation therapy, stem from their adverse effects and increased susceptibility to medications. Despite being seen as innovative options, immune checkpoint inhibitors (ICIs) have rather low clinical response rates. Reliable treatments for patients with metastatic or recurring cervical cancer are currently lacking. Lately, nanomaterials including polymers, liposomes, and dendrimers have been identified as promising delivery vehicles due to their advantages in lower toxicity, enhanced biocompatibility, and tumor-specific administration. This article explores the applications of nanoparticles in cervical cancer treatment, drug delivery, and genome editing utilizing CRISPR technology. Nanoparticles offer a versatile platform for addressing the challenges associated with cervical cancer therapies. By facilitating the precise delivery of therapeutic agents, nanoparticles can enhance the efficacy of treatments while minimizing off-target effects. These nanocarriers can encapsulate chemotherapeutic drugs, enabling controlled release and reducing systemic toxicity. Additionally, advancements in genome-editing technologies, such as CRISPR-Cas9, when combined with nanoparticle-mediated delivery systems, open new avenues for targeting oncogenes and correcting genetic mutations associated with cervical cancer. Furthermore, functionalized nanoparticles can be engineered to exploit the tumor microenvironment, enhancing their accumulation at the tumor site and improving therapeutic outcomes. This innovative approach holds promise for overcoming current limitations and improving patient prognosis

Keywords: immune checkpoint inhibitors , CRISPR-Cas9, cervical cancer , Human Papillomavirus , Oncoproteins

[This article belongs to Research and Reviews : A Journal of Life Sciences ]

How to cite this article:
Neha D. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer. Research and Reviews : A Journal of Life Sciences. 2025; 15(01):30-40.
How to cite this URL:
Neha D. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh. A Brief Review On Nanoparticles Drug Delivery System Used In Cervical Cancer. Research and Reviews : A Journal of Life Sciences. 2025; 15(01):30-40. Available from: https://journals.stmjournals.com/rrjols/article=2025/view=194638


Browse Figures

References

  1. World Health Organization. (2021, Jan 15). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention [Online]. World Health Organization. Available from: https://www.who.int/publications/i/item/97892400308.
  2. Herrero R, Murillo R. Cervical Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer Epidemiology and Prevention. 4th ed. New York: Oxford University Press; 2018. 925–946.
  3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
  4. Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key molecular events in cervical cancer development. Medicina. 2019;55(7):384.
  5. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl. 1):2–23.
  6. De Villier EM, Fauquet C, Broker HU, et al. Classification of Papillomavirus. Virology. 2004;324:17–27.
  7. Pedroza-Saavedra A, Plett-Torres T, Chihu-Amparán L, et al. Molecular bases of human papillomavirus pathogenesis in the development of cervical cancer. In: Davy V-B, editor. Human Papillomavirus and Related Diseases—From Bench to Bedside—Research Aspects. 2012. 249–290p.
  8. Gomez DT, Santos JL. Human papillomavirus infection and cervical cancer: pathogenesis and epidemiology. Commun Curr Res Educ Top Trends Appl Microbiol. 2007;1:680–688.
  9. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127(1):e1–20.
  10. Mignani S, el Kazzouli S, Bousmina M, Majoral JP. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview. Adv Drug Deliv Rev. 2013;65(10):1316–1330.
  11. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
  12. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159(1):14–26.
  13. Jung T, Kamm W, Breitenbach A, et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm. 2000;50(1):147–160.
  14. Liontos M, Kyriazoglou A, Dimitriadis I, et al. Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol Hematol. 2019;137:9–17.
  15. Wang L, Liang TT. CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells. AMB Express. 2020;10(1):54.
  16. Ranghar S, Sirohi P, Verma P, Agarwal V. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz Arch Biol Technol. 2014;57:209–222.
  17. Turos E, Shim JY, Wang Y, et al. Antibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett. 2007;17(1):53–56.
  18. Banerjee SL, Khamrai M, Sarkar K, et al. Modified chitosan encapsulated core-shell Ag Nps for superior antimicrobial and anticancer activity. Int J Biol Macromol. 2016;85:157–167.
  19. Yuan Y, Liu B. Self-assembled nanoparticles based on PEGylated conjugated polyelectrolyte and drug molecules for image-guided drug delivery and photodynamic therapy. ACS Appl Mater Interfaces. 2014;6(17):14903–1410.
  20. Aggarwal U, Goyal AK, Rath G. Development of drug targeting and delivery in cervical cancer. Curr Cancer Drug Targets. 2018;18(8):792–806.
  21. Svenningsen SW, Janaszewska A, Ficker M, et al. Two for the price of one: PAMAM-dendrimers with mixed phosphoryl choline and oligomeric poly(caprolactone) surfaces. Bioconjug Chem. 2016;27(6):1547–1557.
  22. Paris JL, Baeza A, Vallet-Regí M. Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics. Expert Opin Drug Deliv. 2019;16(10):1095–1112.
  23. Cao W, He L, Cao W, et al. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant. Acta Biomater. 2020;112:14–28.
  24. Di Santo R, Digiacomo L, Palchetti S, et al. Microfluidic manufacturing of surface-functionalized graphene oxide nanoflakes for gene delivery. Nanoscale. 2019;11(6):2733–2741.
  25. Xu M, Hu Y, Ding W, et al. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials. 2020;258:120308.
  26. Duo Y, Yang M, Du Z, et al. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy. Acta Biomater. 2018;79:317–330.
  27. Habibi N, Quevedo DF, Gregory JV, Lahann J. Emerging methods in therapeutics using multifunctional nanoparticles. WIREs Nanomed Nanobiotechnol. 2020;12(4):e1625.
  28. Sahu NK, Gupta J, Bahadur D. PEGylated FePt–Fe3O4 composite nanoassemblies (CNAs): in vitro hyperthermia, drug delivery and generation of reactive oxygen species (ROS). Dalton Trans. 2015;44(19):9103–9113.
  29. Chong ZS, Wright GJ, Sharma S. Investigating cellular recognition using CRISPR/Cas9 genetic screening. Trends Cell Biol. 2020;30(8):619–627.
  30. Jiang C, Lin X, Zhao Z. Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends Mol Med. 2019;25(11):1039–1049.
  31. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–869.
  32. Zhou P, Liu W, Cheng Y, Qian D. Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. WIREs Nanomed Nanobiotechnol. 2021;13(5):e1718.
  33. Zhou X, Lian H, Li H, et al. Nanotechnology in cervical cancer immunotherapy: therapeutic vaccines and adoptive cell therapy. Front Pharmacol. 2022;13:1065793.

Jin KT, Lu ZB, Chen JY, et al. Recent trends in nanocarrier-based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater. 2020;2020:9184284

Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 17/12/2024
Accepted 12/01/2025
Published 18/01/2025
340

Login


My IP

PlumX Metrics